FDA Bone Drug Study Offers New Pathway For Plaintiffs
A U.S. Food and Drug Administration analysis published Wednesday suggesting that the benefits of Merck & Co. Inc.'s Fosamax and other osteoporosis drugs may disappear over time will give plaintiffs suing...To view the full article, register now.
Already a subscriber? Click here to view full article